JSM Biotechnology and Biomedical Engineering

Therapeutic Potential of Natural Catechins in Antiviral Activity

Review Article | Open Access

  • 1. Department of Biomedical Engineering, College of Engineering, University of Arkansas Fayetteville, AR 72701, USA
+ Show More - Show Less
Corresponding Authors
Sha Jin, Department of Biomedical Engineering, College of Engineering, University of Arkansas, 700 Research Center Blvd., 3912 ENRC, Fayetteville, AR 72701, USA, Tel: 479-575-5298; Fax: 479-575-7696

Natural compounds have been discovered to be effective in many disease treatments. Among these compounds are epigallocatechin-3-gallate (EGCG) and epicatechin-3-gallate (ECG), two abundant polyphenolic catechins in green tea. They have been found to be able to interfere with many disease-related biochemical processes in vitro. They are capable of suppressing inflammation, tumor growth, bacterial infection, and virus infection. Thus, EGCG and ECG have drawn great attention on the potential effects on disease prevention and treatment of carcinogenic, obesity, diabetic, and Alzheimer’s diseases. In this review, the potential of EGCG and ECG on anti-viral infection is elucidated in detail with an overview of research achievements in this field. The highlight will provide in depth knowledge on new drug discovery and contribute to the design and development of novel anti-virus agents.


Jin S (2013) Therapeutic Potential of Natural Catechins in Antiviral Activity. JSM Biotechnol Bioeng 1(1): 1002.


•    Epigallocatechin-3-gallate
•    Epicatechin-3-gallate
•    Antiviral treatment
•    Viral infection


Current strategies for the treatment of various viral infections highly depend upon the virus type. In recent years, considerable progress has been made in the drug development against virus infections. For instance, AIDS patients can receive combinative therapeutic drugs to inhibit HIV reverse transcriptase and protease activities, so that viral load in the blood and lymphoid tissues can be controlled to an undetectable level. This development has led to a significant improvement in the health and life span of HIV-1infected patients. However, these drugs are toxic and extremely expensive. It is reported that the cost incurred in AIDS treatment is not affordable to 90% of HIV infected patients [1]. The average yearly cost of AIDS therapy and the related health care of affected patients in the USA can run as high as $22,000 [1,2]. Moreover, the emergence of drug resistance further complicates the situation. Therefore, a search for new, effective, and affordable anti-HIV agents became a necessity.

Natural product extracts such as plants have low toxicity, minor side-effects, and they are more cost-effective than chemical drugs. Betulinic acid-like compounds extracted from plants are one example of such extracts that have been reported to possess anti-HIV activity [3]. The betulinic acid-like compound can be isolated from the Chinese herb Syzygium claviflorum [3]. Derived from this compound is an anti-HIV drug called Bevirimat. It inhibits viral maturation [4]. Preclinical studies demonstrated that Bevirimat retains nanomolar inhibitory activity against drug resistant HIV strains. There was no evidence of the virus developing drug resistance against Bevirimat [5]. Other therapeutic compounds from plants are catechin components. The evergreen plant Camellia sinensis produces green tea that maintains its original composition of catechin [6]. Thus, green tea has gained considerable attention as an agent that could reduce the risk of a number of diseases. The natural catechin components in green tea are epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG), epigallocatechin (EGC), and epicatechin. They have been found to be able to interfere with many disease-related biochemical processes in vitro [7,8]. The concentration of the four catechins in a cup of tea is estimated to be approximately one mg per ml, depending on the tea plant, growing environment, manufacturing conditions, and the size of the tea leaves [9,10]. Among the four catechins, EGCG and ECG are the two most abundant catechins in green tea, with EGCG taking up approximately 50% of the total amount of catechins in green tea [11]. EGCG and ECG are also the most effective on suppressing inflammation, tumor growth, bacterial infection, and virus infection both in vitro and in vivo [12]. They are capable of anti-oxidative, anti-carcinogenic, anti-obesity, anti-diabetic, anti-Alzheimer’s disease, and anti-viral activities [13,14] and can even serve as anticancer chemopreventive agents. In addition, they can even provide pronounced cardiovascular and metabolic health benefits [15].

This review focuses on the therapeutic potential of natural catechins for antiviral infections, and highlights the mechanisms of these compounds against viral infection. Figure 1 shows the chemical structure and molecular weight of catechin, ECG, and EGCG. It is the ester of epigallocatechol and gallic acid. The 3-galloyl group plays a critical role in the functional expression of inhibitory effects [16]. The updated information about the therapeutic effect of natural catechins on viral infection may improve the use of catechins and help design novel antiviral drugs.

Anti-HIV infection

AIDS (acquired immunodeficiency syndrome) is a set of symptoms and infections caused by the human immunodeficiency virus (HIV) [17]. HIV-associated reverse transcriptase has been considered as one of the targets for AIDS prevention and treatment because reverse transcriptase is one of the key enzymes in HIV replication. However, most reverse transcriptase inhibitors are toxic and can inhibit cellular DNA polymerases [10,18]. This side effect urged scientists to develop more selective but less toxic medicines for antiviral treatment. Evidence for the anti-viral potential of catechins in green tea has been provided by numerous experimental studies. In 1990, it was reported that the main ingredients of tea catechins EGCG and ECG had strong and selective inhibitory effects on the activity of HIV reverse transcriptase. EGCG and ECG possess gallate ester moieties at the 3 hydroxyl position of the C ring, which could be a key structure for antiviral activity (Figure 1) [8].

The EGCG and ECG, purified from the tea plant, inhibited purified HIV reverse transcriptase much more effectively than they inhibited purified DNA polymerases, as evidently proved by the inhibition constants measured in biochemical assay [19]. These in vitro studies also demonstrated that the concentration required for a 50% inhibition of HIV reverse transcriptase (IC50) was approximately 0.045 µM with Ki value of 2.8 nM [16]. In addition, the results also indicated that both EGCG and ECG are strong inhibitors, especially for HIV-reverse transcriptase. The potential inhibitory efficacy of HIV infection and replication by EGCG in cell culture was reported for the first time in 2002. Fassina and co-works demonstrated that EGCG dose-dependently blocked HIV infection, and 100% inhibition was achieved with 50 µM of EGCG in peripheral blood lymphocyte cultures [18]. Since this study, green tea extracts began to be considered as potential inhibitors of HIV infection in anti-HIV therapy. The power of EGCG on anti-HIV infection is confirmed by Hauber and his coworkers as well [20]. It seems like catechins may help reduce viral load [21]. However, the anti-HIV activity of catechins from green tea has yet to be confirmed in live human trials.

Anti-influenza virus infection

Influenza A virus infection is one of the most common infections of the respiratory tract. It causes pandemic and seasonal diseases and leads to severe mortality in humans and animals. The human influenza caused by this subtype H5N1 of the virus had a high case fatality of 54% [22]. Despite annual updates of flu shots in recent years, vaccines are often ineffective because of the frequent antigenic drift in this RNA virus.

The inhibition effect of EGCG on influenza A and influenza B virus was observed by Nakayama group using electron microscope and haemagglutination assay [19]. Their experimental results revealed that EGCG inhibited the infectivity of influenza A and influenza B virus in Madin-Darby canine kidney (MDCK) cells by binding to the haemagglutinin envelop glycoproteins of influenza virus, and thus prevented the virus from adsorbing to MDCK cells [19]. It was found that EGCG and ECG suppressed the viral RNA synthesis and the release of newly made influenza virus particles from infected cells [23]. Jariwalla and his coworkers have developed a naturally occurring nutrient mixture (NM) to evaluate the effect of NM on human influenza A virus subtype H1N1 infection [24]. This NM contains lysine, poline, ascorbic acid, green tea extract, N-acetyl cysteine, and other micro nutrients. The addition of NM to Vero and MDCK cells post infection induced the inhibition of viral nucleoprotein production in infected cells. Ling and his co-workers orally administrated BALB/c mice with EGCG at varied doses for 5 days. On the 3rd day of the treatment, the mice were infected with influenza A virus. EGCG at 40 mg/kg per day dramatically improved the survival rate of the experimental animals, and also decreased virus replication and the mitigation of viral pneumonia in the lungs [25].

There are at least three mechanisms involved in cell death: apoptosis, necrosis, and reactive oxygen damage. Ling and his coworkers found that 20 nmol/L of EGCG can significantly suppress reactive oxygen species level in MDCK cells following influenza A infection [26]. It is impressive that epicatechin and EGCG also target the brain-derived neurotrophic factor (BDNF) and its precursor pro-BDNF signaling pathways. The simpler structure and efficient blood-brain barrier penetration makes epicatechin to be an effective therapeutic candidate for the treatment of neurological complications of HIV infection [27]. 50% effective inhibition concentrations of EGCG, ECG, and EGC for influenza A virus were 22-28, 22-40, and 309-318 μM, respectively [23].

Anti-hepatitis virus infection

Hepatitis B (HBV) is a major cause of liver disease worldwide and a common coinfection in HIV-infected patients, causing cirrhosis and liver cancer [28,29]. In the U.S., about 1.25 million people are chronically infected with hepatitis B virus (HBV). About 350 million people are estimated to be chronically infected, and 15% to 40% of those people are at risk of developing cirrhosis and/or hepatocellular carcinoma (HCC) [30]. There are currently a number of agents approved for use against HBV. However, the low efficacy, the side-effects, and resistance to HBV mutations of the drugs have encouraged the development of novel therapeutic agents for HBV treatment [31]. The efficacies of green tea extract and the principal component of green tea extract, EGCG, against HBV in a stably expressed HBV cell line have been examined. The experimental results demonstrated that the treatment of green tea extract and/or EGCG inhibited both HBV markers HBsAg and HBeAg in the culture medium in a dose-dependent manner. The IC50 of green tea extract against production of HBsAg and HBeAg were 5.02 and 5.68 µg/ml in culture cells tested. In addition, treatment of the green tea extract at a concentration of 40 µg/ml for six days dramatically inhibited the production of the extracellular HBV DNA and nuclear covalent closed circular DNA in the cells. The founding suggests that green tea extract has the potential to become an anti-HBV infection agent [32]. At a 50% effective concentration (EC(50)) of EGCG of 17.9 μM, hepatitis C virus (HCV) infection was also considerably suppressed. It is clear that EGCG suppresses both HCV entry and RNA replication steps in this type of virus cycle [33]. The observation is consistent with findings that EGCG inhibits HCV infectivity by more than 90% at HCV entry step [34,35]

Anti-HTLV-1 infection

Human T-cell lymphotrophic virus type I (HTLV-1) is a retrovirus and is associated with adult T-cell leukemia. It was estimated that this virus has infected 12 to 25 million people worldwide [36]. It causes acute T-cell leukemia (ATL) and is the first human retrovirus to be isolated [37]. Although only 5% of people with HTLV-1 would develop ATL after 30-40 years of latency period, treatments against ATL are not very effective [38,39]. Thus, the effect of EGCG on cells infected with HTLV1 has been investigated. EGCG induces apoptosis in HTLV-Iinfected and non-infected cells. EGCG can significantly inhibit cell proliferation. The IC50 values differ from cell types. At 96 h of treatment with EGCG, cytotoxicity concentrations ranged from 86 μM to 378 μM among cell types of CEM, C91-PL, HuT102, and Jurkat. CEM cells were the most sensitive to EGCG among the cell types tested [7]. In another study, it was found that when HTLV-I-infected T-cell line and healthy control cells were cultured for 3 days in the presence of 27 µg/ml of EGCG, apoptotic DNA fragmentation was significant in HTLV-1 infected cells compared to the healthy control cells [40]. Moreover, EGCG significantly suppressed not only the growth of peripheral blood T lymphocytes of ATL patients, but also suppressed the expression of HTLV-I pX mRNA for more than 90%. There was minimal growth inhibition of the T cells of normal peripheral blood T lymphocytes (PBLs), and the expression of β-actin mRNA was much less suppressed by this treatment with the same concentration of EGCG, indicating that EGCG specifically targets viral proteins [40]. Sonoda and his co-workers investigated the effect of green tea on the diminishment of HTLV-1 provirus in peripheral blood lymphocytes of 83 asymptomatic HTLV-1 carriers [41]. Daily intakes of the capsulated green tea with an estimated EGCG in the plasma to be about 0.3μg/ml for 5 months can significantly diminish the HTLV-1 provirus load as compared with the controls. However, the in vivo study on anti-HTLV-1 using green tea as a therapeutic agent is very limited. Besides, the inhibitory effect of EGCG to HTLV-1 lacks high specificity. EGCG also inhibits the proliferation of HTLV-1 non-infected cells, as reported by the Harakeh group [7].

Anti-Herpes simplex virus infection

Herpes simplex virus (HSV) infects skin, mucous membranes and nerves. HSV type 1(HSV-1) infects the mouth, lips, or nose, causing cold sores, and HSV-2 infects the genital and anal area. HSV-2 is highly prevalent worldwide and is a leading cause of genital ulcer disease [42]. In particular, it has been demonstrate that HSV-2 infection greatly increases the likelihood of HIV transmission [43]. Isaacs and co-workers studied the inactivation of HSV-2 virions by green tea catechins. Their experimental data showed that EGCG at 100 µM concentration can completely inactivate (10,000-fold) HSV-2 virions and inactivate HSV-1 virions by 3000-fold. When testing the antiviral ability of EGCG with clinical isolates of HSV-1 and HSV-2, 12.5 µM EGCG exhibited approximately 99% inactivation of HSV-2 clinical isolates. All of the HSV-2 clinical strains were completely inactivated when EGCG of 50 µM was applied. Electron microscopy studies illustrated that the envelopes of HSV particles were damaged in the presence of EGCG [44].

Anti-rotavirus, enterovirus and other virus infection

Rotavirus causes gastroenteritis, especially in children. The extracts from green tea leaves also have been used to examine anti-human rotavirus and enterovirus activities [45]. When cells were treated with the mixture of virus supernatant and diluted EGCG, 50% inhibition of cytopathic effect (CPE) to the infection of five species of human rotaviruses was observed at 8 µg/ml ~ 63.0 µg/ml of EGCG. 100% inhibition of CPE of human rotaviruses could be reached at 125 µg/ml of EGCG [45]. Enterovirus is the most common cause of meningitis and can cause serious diseases, especially in infants. 100% inhibition of enterovirus was observed at 250 µg/ml of EGCG for all enteroviruses examined [45]. EGCG and GCG reduced 95% of the titer of infectious progeny enterovirus71 through suppression of the replication of this virus’ genomic RNA according to quantitative real-time PCR analysis [46]. The generation of reactive oxygen species was significantly reduced accordingly with EGCG treatment.

The green tea catechins have been employed to inhibit adenovirus infection in culture cells by Weber and co-workers. Their experimental data demonstrated that addition of 100 µM EGCG to the culture medium of infected cells reduced viral particle production by two orders of magnitude and the virus assembly was greatly reduced at EGCG of 200 µM [47]. Table 1 summarizes the effect of EGCG on a variety of viral infections. The dosages of EGCG vary from the type of cells as well as type of viruses.

Mechanisms of the actions of EGCG interfere with viral infection

Chang and co-workers investigated how the mechanisms of EGCG influence the EBV lytic cycle and revealed that EGCG at 100µM inhibits EBV lytic replication by inhibiting the expression of viral protein EA-D. EGCG did not inhibit the expression of EBV latent protein EBNA-1, which is a DNA binding nuclear phosphoprotein. But EGCG inhibited the transcription of EBV immediate-early genes and thus resulted in a block of EBV lytic cascade [48].

It is well known that CD4 is a cell surface glycoprotein and is expressed on the surface of T-cells. CD4 acts as a receptor for HIV-1 entry and the binding of HIV-1 envelop protein gp120, with CD4 as the first step of HIV-1 entry into target cells. Kawai group employed a competitive ELISA assay to study the interaction between tea polyphenols and CD4. They demonstrated that EGCG, but not ECG, binds to CD4 and interferes with HIV-1 envelope protein gp120 binding to CD4 [49]. Using nuclear magnetic resonance (NMR) spectroscopy, researchers presented evidence that EGCG binds to CD4 tightly to lead to 100% binding at a concentration of 100 µM. In addition, EGCG binds to the CD4 at the polyphenolic rings of catechin and thus blocks the binding sites of CD4 to gp120, resulting in the inhibition of HIV-1 virus entry [50]. With molecular docking (the “best-fit” orientation of a ligand that binds to a particular protein of interest), molecular dynamics simulation, and binding free-energy calculations, it has been found that binding of EGCG with CD4 can effectively block gp120-CD4 binding because the estimated binding affinity of gp120 with the CD4-EGCG complex is negligible [51]. Gp41 is a glycoprotein and provides assistance in viral-cell fusion during HIV entry into the cell. Gp41 conformational changes have also been reported to be significantly inhibited by EGCG, with EGCG blocking the formation of the fusion-active gp41 six-helix bundles, as measured by ELISA [52].

In an attempt to investigate the possible anti-HIV-1 activity of EGCG and its mechanisms of action in the viral life cycle, Yamaguchi et al. found that: 1) the binding of EGCG to both viral particles and cellular surface was reversible after more than two washes. 2) The inhibitory effect of EGCG on HIV-1 infection is cell-type dependent. For instance, a significant dosedependent inhibition on HIV-1 viral DNA synthesis was obtained in monocytoid cells THP-1 and human monocyte-derived macrophage cells (MDM), whereas no considerable inhibition on the viral DNA synthesis was noticed in T-lymphoid H9 cells. 3) Investigation on the effect of EGCG on chronically infected THP1 and H9 cells demonstrated that viral production was dosedependent inhibited in THP-1 cells, as measured by p24 antigen levels in the culture supernatants. However, no reduction in viral production was observed in chronically infected T-lymphoid cells. 4) EGCG did not inhibit viral mRNA synthesis in all the cell lines tested [53]. Taken together, EGCG exerts inhibition on viral infection via several steps of action in the HIV-1 life cycle.

Mechanisms of EGCG interferes with host cell cycle and in vivo studies

In an analysis of ATL-derived HTLV-1-infected cell cycle distribution at which the inhibition was taking place at 300 µM of EGCG, it was found that the cell cycle inhibition occurred at the G0 G1 phase. The expression of transforming growth factor-α TGF-α), a cytokine with proliferative activities, decreased and the expression level of TGF-β2 (a cytokine with apoptotic and antiproliferative effects) increased in all the tested cell lines with EGCG treatment. Besides, four important regulators p21 (a cell cycle inhibitor), p53 (the cell cycle regulator), Bax (an inducer of apoptosis), and Bcl-2α (an inhibitor of apoptosis) for cell cycle and apoptosis were examined. The experimental results revealed that p21, p53, and Bax were up-regulated in EGCG-treated cells (Table 2). While the protein expression of an anti-apoptotic member, Bcl-2α was down-regulated in EGCG-treated cells [7]. These experimental data clearly demonstrated the anti-viral apoptotic signaling pathway with EGCG treatment.

There is limited number of reports on the in vivo study of EGCG against viral infection. However, it was reported that the daily intake of nine capsules of green tea extract “Nanchariki”, which is equivalent to ten cups (120 ml/cup) of green tea for five months, resulted in a significantly diminished human T-cell lymphotropic provirus (HTLV) load in asymptomatic carriers [41]. Using high performance liquid chromatography (HPLC)-UV analysis, it has been determined that nine capsules of the green tea “Nanchariki” contains 246 mg of EGCG. This is no more than one-third of the tolerated dose of green tea in human as reported by Pisters group in a study on maximum-tolerated dose and toxicity of green tea extract to human [54]. With quantitative real-time PCR detection of viral DNA, researchers found that the HTLV-1 provirus load in peripheral blood lymphocytes in the higher provirus load group was diminished after daily intake of the green tea capsules for 5 months [41]. In vitro and in vivo studies also discovered that it is the carbon of the polyphenol ester bond structure in EGCG and ECG that plays the essential role in the inhibition of proteasome in cancer cells. This proteasome inhibition leads to cell growth arrest in the G1 phase of the cell cycle, and thus, contributes to the anti-cancer effect of green tea [55].

Epstein-Barr virus (EBV), also called Human herpesvirus 4 (HHV-4), is one of the most common viruses in humans. It causes infectious mononucleosis, nasopharyngeal carcinoma, and T-cell lymphoma [56-58]. EBV latent infection is strongly implicated in the pathogenesis of several types of cancers, including nasopharyngeal carcinoma (NPC), Hodgkin’s disease, and gastric cancer [59]. Very recently, the effect of EGCG on Epstein-Barr virus (EBV) infection and its mechanisms was also investigated. Interestingly, EGCG inhibits gene transcription and protein levels by decreasing the phosphorylation and activation of extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt [25]. It is concluded that EGCG suppresses the activation of MEK/ERK1/2 and PI3K/Akt signaling, leading to the down-regulation of viral gene transcription and protein expression. Table 2 summarizes the mechanism of EGCG interference with viral infection. EGCG can block virus infection at the early stage of viral entry, receptor binding, and promote apoptosis pathway.


Studies on green tea extracts used as anti-viral infection demonstrated the power of natural product-inspired drug discovery and development. The significant anti-viral activity of green tea offers promise as adjuncts for anti-viral treatment. In 2006, the FDA approved a special extract of green tea as a prescription drug for the external treatment of genital warts caused by the human papilloma virus (HPV) [60]. One exciting update is that a phase I clinical trial for the evaluation of Safety and Toxicity of EGC in HIV-1-Infected individuals started in December 2010, and is estimated to be completed in July, 2013. In this trial, the safety, toxicity, dose, and antiviral effects of EGCG in capsule form (Polyphenon® E) are determined. Individuals are administered orally twice a day at three different doses in HIV-1-infected with a CD+ T lymphocyte count of at least 250 cells/mm3 . There are two groups of adults in this trial. One is treatment-naïve and the other is treatment-experienced adults who are not on concomitant antiretroviral therapy [61]. Concerns such as the toxicity that EGCG might have on normal cells have been illustrated by a number of groups. EGCG at a concentration of up to 20 µM did not present any damage to rhesus monkey kidney epithelial cells when compared to the control [62]. EGCG is a small molecule with a molecular weight of 458.4. It has been approved as a safe compound by the FDA. However, it should be pointed out that the concentration of EGCG in drinking tea is not sufficient to inhibit disease-related molecules. Thus, up to one gram of green tea solids would be appreciable for anti-disease treatment [54]. EGCG and ECG can be administered orally and are available from the tea plant. It does not cost much for them to be isolated. Besides, as a popular drink, teas are much safer than traditional drugs. Therefore, they offer great advantages over traditional drugs, indicating that EGCG can be a potential therapeutic agent or can act in adjunctive therapy against virus infection.

It should be pointed out that the use of green tea catechins as therapeutic agents has been limited by the catechins’ low bioavailability, poor stability under physiological conditions, and intestinal absorption in the body. Hence, like almost all of therapeutic agents, targeted delivery against virus replication is still a major challenge. One approach is to utilize nanotechnology for the targeted delivery of catechins. For example, EGCG can be encapsulated into chitosan-coated nanoliposomes [63]. Chitosan nanoparticles can significantly enhance the intestinal absorption of the green tea catechins due to the stabilization of catechins after encapsulation [64]. To improve bioavailability, surface engineering can also be applied to manufacture tea nanoliposome by a thin film ultrasonic dispersion method [65]. Analogs can be synthesized to improve the stability and bioavailability of EGCG [66].

On the other hand, designing and synthesizing a molecule based on the structure of the natural compound is a major strategy for the development of novel drugs. Song and his coworkers synthesized catechin derivatives with different alkyl chain lengths and aromatic ring substitutions at the 3-hydroxyl group. They investigated the anti-influenza virus activity and cytotoxicity of these EGC derivatives [67]. While modifications of the 5’-hydroxyl group of the trihydroxy benzyl moiety did not notably contribute to antiviral activity, the derivatives carrying chain length (7-9 carbons) showed significant antiviral activity with minimum inhibition concentrations of 5-10 μM in red blood cells. Importantly, the derivatives can inhibit at least five influenza subtypes including human influenza viruses (type A/ H1N1, A/H3N2, and B), H2N2, and H9N2 avian influenza virus, showing a potential cross-protection from influenza pandemic [67].The introduction of long alkyl chains of EGCG by Mori’s group enhanced anti-influenza H1N1 virus activity by 24-fold compared to native EGCG [68]. Nevertheless, drug discovery for anti-viral infection is a challenge due to the development of drug resistance by varied viruses. Recent anti-viral researches have shown that a combination strategy may combat viral infection. For instance, an inhibitor of virus infection combining with an anti-inflammatory agent can improve the treatment of viral infection [69]. Taken together, green tea extract EGCG demonstrates its potential as a therapeutic agent. Nevertheless, more studies are necessary for targeted delivery, improved stability, and for the extract to act as an adjuvant for anti-viral treatment.


1. Bourinbaiar AS, Jirathitikal V. Low-cost anti-HIV compounds: potential application for AIDS therapy in developing countries. Curr Pharm Des. 2003; 9: 1419-31.

2. Wang J, Wang HX, Ng TB. A peptide with HIV-1 reverse transcriptase inhibitory activity from the medicinal mushroom Russula paludosa. Peptides. 2007; 28: 560-5.

3. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/ pharmacodynamics of single-dose 3-o-(3’,3’-dimethylsuccinyl) betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007; 51: 3574-81.

4. Martin DE, Blum R, Wilton J, Doto J, Galbraith H, Burgess GL, et al. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother. 2007; 51: 3063-6.

5. Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin Pharmacother. 2011; 12: 31-46.

6. Mukhtar H, Ahmad N. Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr. 2000; 71: 1698S-702S.

7. Harakeh S, Abu-El-Ardat K, Diab-Assaf M, Niedzwiecki A, El-Sabban M, Rath M. Epigallocatechin-3-gallate induces apoptosis and cell cycle arrest in HTLV-1-positive and -negative leukemia cells. Med Oncol. 2008; 25: 30-9.

8. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med. 1996; 20: 933-56.

9. Kanaka S, Kim M., Taniguchi M., Yamamoto T. Antibacterial substances in Japanese green tea extract against streptococcus mutants, a cariogenic bacterium. Agricultural and Biological Chemistry. 1989; 53: 2307-2311.

10. Astill C, Birch MR, Dacombe C, Humphrey PG, Martin PT. Factors affecting the caffeine and polyphenol contents of black and green tea infusions. J Agric Food Chem. 2001; 49: 5340-7.

11. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr. 1997; 37: 693-704.

12. Bushman JL. Green tea and cancer in humans: a review of the literature. Nutr Cancer. 1998; 31: 151-9.

13. Khan N, Mukhtar H. Tea polyphenols for health promotion. Life Sci. 2007; 81: 519-33.

14. Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM, Namkoong SE, et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev. 2003; 12: 383-90.

15. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr. 2007; 26: 373S-388S.

16. Nakane H, Ono K. Differential inhibitory effects of some catechin derivatives on the activities of human immunodeficiency virus reverse transcriptase and cellular deoxyribonucleic and ribonucleic acid polymerases. Biochemistry. 1990; 29: 2841-5.

17. Sleasman JW, Goodenow MM. 13. HIV-1 infection. J Allergy Clin Immunol. 2003; 111: S582-92.

18. Fassina G, Buffa A, Benelli R, Varnier OE, Noonan DM, Albini A. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS. 2002; 16: 939-41.

19. Nakayama M, Suzuki K, Toda M, Okubo S, Hara Y, Shimamura T. Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res. 1993; 21: 289-99.

20. Hauber I, Hohenberg H, Holstermann B, Hunstein W, Hauber J. The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc Natl Acad Sci U S A. 2009; 106: 9033-8.

21. Nance CL, Shearer WT. Is green tea good for HIV-1 infection?. J Allergy Clin Immunol. 2003; 112: 851-3. 22.Lahariya C, Sharma AK, Pradhan SK. Avian flu and possible human pandemic. Indian Pediatr. 2006; 43: 317-25.

23. Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005; 68: 66-74.

24. Jariwalla RJ, Roomi MW, Gangapurkar B, Kalinovsky T, Niedzwiecki A, Rath M. Suppression of influenza A virus nuclear antigen production and neuraminidase activity by a nutrient mixture containing ascorbic acid, green tea extract and amino acids. Biofactors 2007;31(1):1-15.

25. Liu S, Li H, Chen L, Yang L, Li L, Tao Y, et al. (-)-Epigallocatechin-3- gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells. Carcinogenesis. 2013; 34: 627-37.

26. Ling JX, Wei F, Li N, Li JL, Chen LJ, Liu YY, et al. Amelioration of influenza virus-induced reactive oxygen species formation by epigallocatechin gallate derived from green tea. Acta Pharmacol Sin. 2012; 33: 1533- 41.

27. Nath S, Bachani M, Harshavardhana D, Steiner JP. Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF pathway. J Neurovirol. 2012; 18: 445-55.

28. Kitchell E, Jain MK. Evaluation and treatment of the patient coinfected with hepatitis B and HIV. Curr HIV/AIDS Rep. 2008; 5: 103-11.

29. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature. 1980; 286: 533-5.

30. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005; 25: 3-8.

31. Férir G, Kaptein S, Neyts J, De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol. 2008; 18: 19-34.

32. Xu J, Wang J, Deng F, Hu Z, Wang H. Green tea extract and its major component epigallocatechin gallate inhibits hepatitis B virus in vitro. Antiviral Res. 2008; 78: 242-9.

33. Chen C, Qiu H, Gong J, Liu Q, Xiao H, Chen XW, et al. (-)-Epigallocatechin3-gallate inhibits the replication cycle of hepatitis C virus. Arch Virol. 2012; 157: 1301-12.

34. Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, et al. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology. 2012; 55: 720-9.

35. Ciesek S, von Hahn T, Colpitts CC, Schang LM, Friesland M, Steinmann J, et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology. 2011; 54: 1947-55.

36. Liao JB. Viruses and human cancer. Yale J Biol Med. 2006; 79: 115-22.

37. Hinuma Y. A retrovirus associated with a human leukemia, adult T-cell leukemia. Curr Top Microbiol Immunol. 1985; 115: 127-41.

38. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995; 332: 1749-51.

39. Macchi B, Faraoni I, Zhang J, Grelli S, Favalli C, Mastino A, et al. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J Gen Virol. 1997; 78: 1007-16.

40. Li HC, Yashiki S, Sonoda J, Lou H, Ghosh SK, Byrnes JJ, et al. Green tea polyphenols induce apoptosis in vitro in peripheral blood T lymphocytes of adult T-cell leukemia patients. Jpn J Cancer Res. 2000; 91: 34-40.

41. Sonoda J, Koriyama C, Yamamoto S, Kozako T, Li HC, Lema C, et al. HTLV-1 provirus load in peripheral blood lymphocytes of HTLV-1 carriers is diminished by green tea drinking. Cancer Sci. 2004; 95: 596-601.

42. Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect. 2007; 83: 16-22.

43. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, WabwireMangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342: 921-9.

44. Isaacs CE, Wen GY, Xu W, Jia JH, Rohan L, Corbo C, et al. Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob Agents Chemother. 2008; 52: 962-70.

45. Mukoyama A, Ushijima H, Nishimura S, Koike H, Toda M, Hara Y, et al. Inhibition of rotavirus and enterovirus infections by tea extracts. Jpn J Med Sci Biol. 1991; 44: 181-6.

46. Ho HY, Cheng ML, Weng SF, Leu YL, Chiu DT. Antiviral effect of epigallocatechin gallate on enterovirus 71. J Agric Food Chem. 2009; 57: 6140-7.

47. Weber JM, Ruzindana-Umunyana A, Imbeault L, Sircar S. Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res. 2003; 58: 167-73.

48. Chang LK, Wei TT, Chiu YF, Tung CP, Chuang JY, Hung SK, et al. Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate. Biochem Biophys Res Commun. 2003; 301: 1062-8.

49. Kawai K, Tsuno NH, Kitayama J, Okaji Y, Yazawa K, Asakage M, et al. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J Allergy Clin Immunol. 2003; 112: 951-7.

50. Williamson MP, McCormick TG, Nance CL, Shearer WT. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy. J Allergy Clin Immunol. 2006; 118: 1369-74.

51. Hamza A, Zhan CG. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. J Phys Chem B. 2006; 110: 2910-7.

52. Liu S, Lu H, Zhao Q, He Y, Niu J, Debnath AK, Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta. 2005; 1723: 270-81.

53. Yamaguchi K, Honda M, Ikigai H, Hara Y, Shimamura T. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 2002; 53: 19- 34.

54. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001; 19: 1830-8.

55. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem. 2001; 276: 13322-30.

56. Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, Wahl R, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med. 1988; 318: 733- 41.

57. Niedobitek G, Hamilton-Dutoit S, Herbst H, Finn T, Vetner M, Pallesen G, et al. Identification of Epstein-Barr virus-infected cells in tonsils of acute infectious mononucleosis by in situ hybridization. Hum Pathol. 1989; 20: 796-9.

58. Su IJ, Hsieh HC, Lin KH, Uen WC, Kao CL, Chen CJ, et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. Blood. 1991; 77: 799-808.

59. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003; 22: 5108-21.

60. Blumenthal M. FDA Approves Special Green Tea Extract as a New Topical Drug for Genital Warts Expert Says Development Marks the Birth of a “New Industry”. HerbalGram. 2007;74:62-63.

61. http://clinicaltrials.gov/show/NCT01433289%202013.

62. Vance SH, Tucci M, Benghuzzi H. Pathophysiological response of rhesus monkey kidney epithelial cells exposed to epigallocatechin-3- gallate. Biomed Sci Instrum. 2005; 41: 223-8.

63. de Pace RC, Liu X, Sun M, Nie S, Zhang J, Cai Q, et al. Anticancer activities of (-)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. J Liposome Res. 2013; 23: 187-96.

64. Dube A, Nicolazzo JA, Larson I. Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci. 2010; 41: 219-25.

65. Lu Q, Li DC, Jiang JG. Preparation of a tea polyphenol nanoliposome system and its physicochemical properties. J Agric Food Chem. 2011; 59: 13004-11.

66. Yang H, Landis-Piwowar K, Chan TH, Dou QP. Green tea polyphenols as proteasome inhibitors: implication in chemoprevention. Curr Cancer Drug Targets. 2011; 11: 296-306.

67. Song JM, Park KD, Lee KH, Byun YH, Park JH, Kim SH, et al. Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Res. 2007; 76: 178-85.

68. Mori S, Miyake S, Kobe T, Nakaya T, Fuller SD, Kato N, et al. Enhanced anti-influenza A virus activity of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives: effect of alkyl chain length. Bioorg Med Chem Lett. 2008; 18: 4249-52.

69. Littler E, Oberg B. Achievements and challenges in antiviral drug discovery. Antivir Chem Chemother. 2005; 16: 155-68.

Received : 09 Jul 2013
Accepted : 29 Jul 2013
Published : 31 Jul 2013
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
TEST Journal of Dentistry
ISSN : 1234-5678
Launched : 2014
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X